Protein Expression News and Research

RSS

Scientists develop a high-throughput, cell-free screening platform for anti-SARS-CoV-2 antibody discovery

Scientists from Northwestern University, USA, have recently developed a high-throughput, automated screening platform to rapidly identify anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. The study is currently available on the bioRxiv* preprint server.

8 Nov 2021

Hemin as a potential therapy for COVID-19

The current study explores the antiviral activity of HO-1 induced by hemin against SARS-CoV-2 and attempts to describe the mechanism of its anti-viral action.

8 Nov 2021

Researchers develop a new test to more easily diagnose medulloblastoma

Researchers at the University of British Columbia and BC Cancer, in partnership with BC Children's Hospital Research Institute, have developed a new test to more easily diagnose medulloblastoma, the most common malignant childhood brain tumor.

1 Nov 2021

Researchers develop eToeholds for safe, effective RNA and cellular therapies

RNAs are best known as the molecules that translate information encoded in genes into proteins with their myriad of activities.

29 Oct 2021

Sexually dimorphic placental antibody transfer during SARS-CoV-2 infection

In a paper recently published in the journal Science Translational Medicine by Bordt et al. (October 19th, 2021), maternal SARS-CoV-2 infections are studied with particular regard to maternal-fetal antibody transfer and virus-induced placental interferon responses, finding a sexually dimorphic response that results in lesser antibody transfer to the male fetus.

26 Oct 2021

Research reveals the mechanisms of cardiac sex disparities at an early stage

Males and females differ in prevalence, treatment responses, and survival rates for a variety of diseases. For cardiac disease, women almost uniformly fare far worse than men. There are likely many reasons for this, and scientists at the University of North Carolina at Chapel Hill and Princeton University seemed to have found one deep inside cells before we're even born.

21 Oct 2021

U-M researchers target a protein channel in the cell’s lysosome to selectively kill cancer cells

Cancer treatments necessarily target unchecked cell growth, and selectively kill cancer cells while sparing normal cells and avoiding general toxicity in the human body.

20 Oct 2021

Engineered 3D scaffolds of human brown adipose tissue as a new therapeutic strategy for obesity and diabetes

A group of researchers from various institutes in the USA addressed the limitations of BAT therapy by transplanting a low dose of brown adipocytes (BAs) without Matrigel to determine if this could alleviate high-fat diet-induced OB, metabolic symptoms, and T2DM in mice.

18 Oct 2021

Delta variant exhibits immune evasion, enhanced cell entry, and augmented syncytium formation

Researchers addressed the question of using reporter particles pseudotyped with the S protein of SARS-CoV-2, which are suitable tools to examine SARS-CoV-2 neutralization antibodies.

11 Oct 2021

Adapting biological research and development to COVID-19

In this interview, News-Medical talks to Dr Yuning Chen, about the work he does with Sino Biological and how they have adapted their research & development to the COVID-19 pandemic.

From Sino Biological Inc. 8 Oct 2021

Human coronavirus replicates in bats without using the spike protein

Researchers in Singapore have conducted a study showing active replication of a human coronavirus in bats that occurred without the viral spike protein binding to host cell receptors.

28 Sep 2021

Researchers discover protein previously unknown to be involved in SARS-CoV-2 infection

Researchers in the UK and Germany have provided evidence for a novel mechanism by which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – binds to human host cells.

27 Sep 2021

Design of mRNA vaccines to combat COVID-19

A recent review study discusses fundamental concepts in the successful delivery of nucleic acids in therapeutics.

23 Sep 2021

Comparison of recombinant SARS-CoV-2 receptor binding domain produced in mammalian, insect, and bacterial cells

In a recent study, RBD produced in various cell types are characterized in-depth, comparing their applicability for future COVID-19 research.

21 Sep 2021

Role of extracellular vesicles embedded with engineered ACE2 in the neutralization of the SARS-CoV-2 pseudovirus

Researchers discuss the preparation and characterization of EVs-ACE2, along with the production and characterization of SARS-CoV-2 S-pseudovirus.

20 Sep 2021

Flu shots and COVID-19 immunity

A new paper finds that the influenza vaccine may influence both the response to and incidence of infection by the SARS-CoV-2.

14 Sep 2021

JunD promotes epithelial-to-mesenchymal transition by association with NEAT1 lncRNA

Oncotarget published "JunD accentuates arecoline-induced disruption of tight junctions and promotes epithelial-to-mesenchymal transition by association with NEAT1 lncRNA" which reported that the effects of low and high concentrations of arecoline on the stability of tight junctions and EMT induction were studied.

3 Sep 2021

Could genetic variants in host cell receptors (ACE2) explain COVID-19 susceptibility among certain ethnic groups?

Led by Ioannis Karakikes of Stanford University, a new study suggests some hospitalized patients with COVID-19 contain ACE2 genetic variants that increase ACE2 expression. Some variants that altered ACE2 protein expression and binding affinity were more prevalent in people with European backgrounds.

30 Aug 2021

Study reveals how SARS-CoV-2 variants of concern modulate receptor and antibody binding

In a trailblazing engineering effort, Canadian and US researchers indicate that the emergence of novel variants of SARS-CoV-2 stems from the mutations of spike glycoprotein that confer either increased affinity for the host cell receptor or increased antibody evasion.

30 Aug 2021

Polymeric and lipid nanoparticles in self-amplifying RNA vaccines result in higher protein expression and immunogenicity

Self-amplifying RNA (saRNA) is an advanced platform for nucleic acid vaccine development. The backbone is typically derived from an alphaviral genome and encodes a gene of interest (GOI) and a viral replicase that can amplify the genomic and subgenomic RNA.

30 Aug 2021

Protein Expression News and Research

Scientists develop a high-throughput, cell-free screening platform for anti-SARS-CoV-2 antibody discovery

Hemin as a potential therapy for COVID-19

Researchers develop a new test to more easily diagnose medulloblastoma

Researchers develop eToeholds for safe, effective RNA and cellular therapies

Sexually dimorphic placental antibody transfer during SARS-CoV-2 infection

Research reveals the mechanisms of cardiac sex disparities at an early stage

U-M researchers target a protein channel in the cell’s lysosome to selectively kill cancer cells

Engineered 3D scaffolds of human brown adipose tissue as a new therapeutic strategy for obesity and diabetes

Delta variant exhibits immune evasion, enhanced cell entry, and augmented syncytium formation

Adapting biological research and development to COVID-19

Human coronavirus replicates in bats without using the spike protein

Researchers discover protein previously unknown to be involved in SARS-CoV-2 infection

Design of mRNA vaccines to combat COVID-19

Comparison of recombinant SARS-CoV-2 receptor binding domain produced in mammalian, insect, and bacterial cells

Role of extracellular vesicles embedded with engineered ACE2 in the neutralization of the SARS-CoV-2 pseudovirus

Flu shots and COVID-19 immunity

JunD promotes epithelial-to-mesenchymal transition by association with NEAT1 lncRNA

Could genetic variants in host cell receptors (ACE2) explain COVID-19 susceptibility among certain ethnic groups?

Study reveals how SARS-CoV-2 variants of concern modulate receptor and antibody binding

Polymeric and lipid nanoparticles in self-amplifying RNA vaccines result in higher protein expression and immunogenicity

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News